Anika Therapeutics, Inc. (ANIK) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Medical - Devices
EV/EBITDA
↑
N/A
—
5yr avg: 34.26
30Y Low4.5·High70.4
P/FCF
↓
44.30
↓-54% vs avg
5yr avg: 96.36
30Y Low4.5·High161.1
P/B Ratio
↓
1.44
-3% vs avg
5yr avg: 1.49
30Y Low0.3·High5.9
ROE
↓
-7.3%
↓+51% vs avg
5yr avg: -15.0%
30Y Low-50%·High46%
Debt/EBITDA
↑
N/A
—
5yr avg: 3.34
30Y Low0.3·High8.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ANIK Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Anika Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 44.3x P/FCF, 54% below the 5-year average of 96.4x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $193M | $138M | $242M | $332M | $431M | $524M | $644M | $745M | $494M | $812M | $740M |
| Enterprise Value | $160M | $105M | $213M | $291M | $376M | $451M | $570M | $610M | $405M | $679M | $636M |
| P/E Ratio → | -18.97 | — | — | — | — | 127.96 | — | 27.43 | 26.46 | 25.55 | 22.77 |
| P/S Ratio | 1.71 | 1.22 | 2.02 | 2.75 | 3.79 | 3.55 | 4.93 | 6.50 | 4.68 | 7.16 | 7.16 |
| P/B Ratio | 1.44 | 0.96 | 1.57 | 1.56 | 1.51 | 1.83 | 2.36 | 2.58 | 1.87 | 3.08 | 3.32 |
| P/FCF | 44.30 | 31.59 | — | — | — | 161.14 | 56.28 | 21.81 | 16.31 | 25.52 | 75.62 |
| P/OCF | 17.27 | 12.32 | 44.85 | — | 97.76 | 62.44 | 49.27 | 20.14 | 14.14 | 19.90 | 31.09 |
P/E links to full P/E history page with 30-year chart
ANIK EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.93 | 1.77 | 2.41 | 3.30 | 3.05 | 4.37 | 5.33 | 3.83 | 5.99 | 6.15 |
| EV / EBITDA | — | — | 70.40 | 19.33 | 20.68 | 26.63 | — | 15.17 | 14.63 | 13.58 | 11.70 |
| EV / EBIT | — | — | — | 344.91 | 102.33 | — | — | 17.82 | 18.61 | 14.85 | 12.56 |
| EV / FCF | — | 23.96 | — | — | — | 138.57 | 49.87 | 17.86 | 13.37 | 21.33 | 64.97 |
ANIK Profitability
Margins and return-on-capital ratios measuring operating efficiency
Anika Therapeutics, Inc. earns an operating margin of -9.8%. Operating margins have compressed from 0.7% to -9.8% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -7.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.6% | 56.6% | 63.4% | 68.3% | 64.3% | 56.1% | 52.9% | 74.9% | 70.4% | 75.9% | 76.8% |
| Operating Margin | -9.8% | -9.8% | -4.3% | 0.7% | 3.2% | 1.8% | -21.7% | 29.9% | 20.6% | 40.3% | 49.0% |
| Net Profit Margin | -9.6% | -9.6% | -47.0% | -68.4% | -13.1% | 2.8% | -18.4% | 23.7% | 17.7% | 28.1% | 31.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -7.3% | -7.3% | -30.8% | -33.2% | -5.2% | 1.5% | -8.6% | 9.9% | 7.1% | 13.1% | 15.0% |
| ROA | -5.5% | -5.5% | -23.8% | -26.7% | -4.3% | 1.2% | -6.9% | 8.9% | 6.7% | 12.2% | 13.7% |
| ROIC | -7.1% | -7.1% | -2.6% | 0.3% | 1.2% | 1.0% | -12.1% | 15.7% | 10.7% | 27.6% | 34.7% |
| ROCE | -6.4% | -6.4% | -2.4% | 0.3% | 1.1% | 0.8% | -8.8% | 11.8% | 8.1% | 18.3% | 22.5% |
ANIK Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $57M exceeds total debt of $24M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.17 | 0.17 | 0.13 | 0.11 | 0.07 | 0.08 | 0.08 | — | — | — |
| Debt / EBITDA | — | — | 8.59 | 1.84 | 1.70 | 1.24 | — | 0.56 | — | — | — |
| Net Debt / Equity | — | -0.23 | -0.19 | -0.19 | -0.19 | -0.26 | -0.27 | -0.47 | -0.34 | -0.51 | -0.47 |
| Net Debt / EBITDA | — | — | -9.83 | -2.72 | -3.05 | -4.34 | — | -3.35 | -3.22 | -2.66 | -1.92 |
| Debt / FCF | — | -7.63 | — | — | — | -22.57 | -6.41 | -3.95 | -2.94 | -4.19 | -10.65 |
| Interest Coverage | — | — | — | — | — | — | -18.09 | — | — | — | — |
Net cash position: cash ($57M) exceeds total debt ($24M)
ANIK Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Anika Therapeutics, Inc.'s current ratio of 4.72x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.86x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 5.26x to 4.72x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.72 | 4.72 | 4.88 | 5.26 | 6.07 | 5.66 | 4.81 | 14.39 | 17.98 | 15.78 | 19.37 |
| Quick Ratio | 3.86 | 3.86 | 3.85 | 4.47 | 4.65 | 4.45 | 3.56 | 13.04 | 16.09 | 14.10 | 17.55 |
| Cash Ratio | 2.62 | 2.62 | 2.39 | 2.21 | 3.09 | 3.17 | 2.67 | 11.36 | 14.09 | 12.03 | 14.18 |
| Asset Turnover | — | 0.59 | 0.59 | 0.45 | 0.33 | 0.43 | 0.36 | 0.35 | 0.38 | 0.40 | 0.43 |
| Inventory Turnover | 2.61 | 2.61 | 1.84 | 1.57 | 1.02 | 1.80 | 1.33 | 1.31 | 1.47 | 1.24 | 1.50 |
| Days Sales Outstanding | — | 76.64 | 71.82 | 79.65 | 111.04 | 73.70 | 67.43 | 73.50 | 71.84 | 76.67 | 97.44 |
ANIK Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Anika Therapeutics, Inc. returns 4.9% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 0.8% | — | 3.6% | 3.8% | 3.9% | 4.4% |
| FCF Yield | 2.3% | 3.2% | — | — | — | 0.6% | 1.8% | 4.6% | 6.1% | 3.9% | 1.3% |
| Buyback Yield | 4.9% | 6.9% | 4.5% | 1.5% | 0.0% | 0.0% | 0.0% | 4.0% | 6.1% | 0.0% | 3.4% |
| Total Shareholder Yield | 4.9% | 6.9% | 4.5% | 1.5% | 0.0% | 0.0% | 0.0% | 4.0% | 6.1% | 0.0% | 3.4% |
| Shares Outstanding | — | $14M | $15M | $15M | $15M | $15M | $14M | $14M | $15M | $15M | $15M |
Peer Comparison
Compare ANIK with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ANIKYou | $193M | -19.0 | — | 44.3 | 56.6% | -9.8% | -7.3% | -7.1% | — |
 MDXG | $545M | 11.5 | 5.1 | 7.5 | 82.6% | 15.3% | 21.6% | 42.3% | 0.3 |
 NVCR | $2B | -11.7 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 OSUR | $306M | -4.5 | — | — | 41.9% | -59.2% | -18.3% | -20.0% | — |
 ATRC | $1B | -120.0 | 80.7 | 30.2 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 LNTH | $7B | 30.5 | 16.8 | 19.1 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 HALO | $8B | 26.8 | 11.2 | 12.6 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 |
 ALGN | $13B | 32.2 | 15.2 | 26.6 | 68.3% | 15.3% | 10.4% | 15.4% | 0.1 |
 GMED | $11B | 20.2 | 17.1 | 18.1 | 67.4% | 16.3% | 12.3% | 8.9% | 0.2 |
 PRGO | $1B | -1.0 | 7.1 | 9.8 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 OFIX | $382M | -4.1 | — | — | 67.1% | -8.3% | -19.3% | -8.6% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
ANIK — Frequently Asked Questions
Quick answers to the most common questions about buying ANIK stock.
What is Anika Therapeutics, Inc.'s P/E ratio?
Anika Therapeutics, Inc.'s current P/E ratio is -19.0x. The historical average is 31.9x.
What is Anika Therapeutics, Inc.'s ROE?
Anika Therapeutics, Inc.'s return on equity (ROE) is -7.3%. The historical average is 2.7%.
Is ANIK stock overvalued?
Based on historical data, Anika Therapeutics, Inc. is trading at a P/E of -19.0x. Compare with industry peers and growth rates for a complete picture.
What are Anika Therapeutics, Inc.'s profit margins?
Anika Therapeutics, Inc. has 56.6% gross margin and -9.8% operating margin.